Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

JOURNAL ARTICLE published May 2010 in European Urology

Authors: Bertrand Tombal | Kurt Miller | Laurent Boccon-Gibod | Fritz Schröder | Neal Shore | E. David Crawford | Judd Moul | Jens-Kristian Jensen | Tine Kold Olesen | Bo-Eric Persson